research Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin
Finasteride interacts with terazosin, but not doxazosin; caution needed.
Search
for
Sort by
Research
300-330 / 1000+ results 
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Estimation of health utility values for alopecia areata
More severe hair loss in alopecia areata greatly impacts patients and caregivers.
research Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
research Alopecia Areata Universalis Precipitated by SARS-CoV-2 Vaccine: A Case Report and Narrative Review
The SARS-CoV-2 vaccine may be linked to triggering autoimmune conditions like Alopecia Areata.
research The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
The main goal for new Alopecia Areata treatments should be significant improvement in scalp hair growth.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
research Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
Laser treatment and deroofing are effective options for hidradenitis suppurativa.
research Comment on “Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series”: Adding further evidence about side effects
Low-dose oral minoxidil for hair loss seems to have rare side effects, but more research is needed to confirm its safety.
research Prescribing to save patients money: Ethical considerations
Doctors should prescribe cheaper, off-label medication and teach patients how to use it to save money ethically.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Demographics and Clinical Characteristics among Patients with Distinct Psychosocial Burden Profiles Related to Vitiligo: Results of a Latent Class Analysis
Vitiligo's impact varies widely, affecting both emotions and social life, not just physical symptoms.
research Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
research Alopecia Areata: The Clinician and Patient Voice
Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
research Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease
A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.
research Tratamento adjuvante com minoxidil oral para tratamento de alopecia areata refratária a inibidores de JAK
Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
research Health Utility of Facial Angiofibroma associated with Tuberous Sclerosis Complex
Moderate facial angiofibroma significantly reduces quality of life compared to almost-clear cases, highlighting the benefits of treatment.
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research Assessing the Merit of the Apple Cider Vinegar Rinse Method for Synthetic Hair Extensions
Apple cider vinegar rinses for synthetic hair extensions lack scientific proof of reducing harmful chemicals.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Consider Cultural Practices and Barriers to Care When Treating Alopecia Areata
Consider cultural practices and barriers for effective alopecia areata treatment.
research Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.